Abstract
Perinatal hypoxia-ischemia (HI) is an important cause of neonatal brain injury. Recent progress in the search for neuroprotective compounds has provided us with several promising drugs to reduce perinatal HI-induced brain injury. In the early stage (first 6 hours after birth) therapies are concentrated on prevention of the production of reactive oxygen species or free radicals (xanthine-oxidase-, nitric oxide synthase-, and prostaglandin inhibition), anti-inflammatory effects (erythropoietin, melatonin, Xenon) and anti-apoptotic interventions (nuclear factor kappa B- and c-jun N-terminal kinase inhibition); in a later stage stimulation of neurotrophic properties in the neonatal brain (erythropoietin, growth factors) can be targeted to promote neuronal and oligodendrocyte regeneration. Combination of pharmacological means of treatment with moderate hypothermia, which is accepted now as a meaningful therapy, is probably the next step in clinical treatment to fight post-asphyxial brain damage. Further studies should be directed at a more rational use of therapies by determining the optimal time and dose to inhibit the different potentially destructive molecular pathways or to enhance endogenous repair while at the same time avoiding adverse effects of the drugs used.
Keywords: Brain, hypoxia, ischemia, neonate, neuroprotection, pharmacology, neonatal brain injury, nitric oxide synthase, prostaglandin inhibition, xanthine-oxidase, erythropoietin, melatonin, Xenon, anti-apoptotic, reoxygenation, hypothermia, neurotransmitters, glutamate, N-methyl-D-aspartate, free radi-cals, hydrogen peroxide, neutrophils, macrophages, microglia, N-terminal kinase, Growth Factors, peroxynitrite, free radicals, neurogenesis, anti-oxidative, anti-inflammatory, asphyxia, nicardipine, Calcium blockers, flunarizine, hydroxyl radicals, prostaglandin, Allopurinol, chelate, oxypurinol, asphyxiated, pro-free radical, ameliorate, 7-nitroindazole, aminoguanidine, erythroid progenitor, astrocytes, microglial cells, umbilical, etanercept, TNF-receptor, Domain, intraperitoneally, caspase-3, Hyperbaric Oxygen, sensorimotor, Post-HI Period, Trophic Factor, subventricular, oligodendrocytes, angiogenesis
Current Neuropharmacology
Title: Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic Brain Injury
Volume: 8 Issue: 4
Author(s): Xiyong Fan, Annemieke Kavelaars, Cobi J. Heijnen, Floris Groenendaal and Frank van Bel
Affiliation:
Keywords: Brain, hypoxia, ischemia, neonate, neuroprotection, pharmacology, neonatal brain injury, nitric oxide synthase, prostaglandin inhibition, xanthine-oxidase, erythropoietin, melatonin, Xenon, anti-apoptotic, reoxygenation, hypothermia, neurotransmitters, glutamate, N-methyl-D-aspartate, free radi-cals, hydrogen peroxide, neutrophils, macrophages, microglia, N-terminal kinase, Growth Factors, peroxynitrite, free radicals, neurogenesis, anti-oxidative, anti-inflammatory, asphyxia, nicardipine, Calcium blockers, flunarizine, hydroxyl radicals, prostaglandin, Allopurinol, chelate, oxypurinol, asphyxiated, pro-free radical, ameliorate, 7-nitroindazole, aminoguanidine, erythroid progenitor, astrocytes, microglial cells, umbilical, etanercept, TNF-receptor, Domain, intraperitoneally, caspase-3, Hyperbaric Oxygen, sensorimotor, Post-HI Period, Trophic Factor, subventricular, oligodendrocytes, angiogenesis
Abstract: Perinatal hypoxia-ischemia (HI) is an important cause of neonatal brain injury. Recent progress in the search for neuroprotective compounds has provided us with several promising drugs to reduce perinatal HI-induced brain injury. In the early stage (first 6 hours after birth) therapies are concentrated on prevention of the production of reactive oxygen species or free radicals (xanthine-oxidase-, nitric oxide synthase-, and prostaglandin inhibition), anti-inflammatory effects (erythropoietin, melatonin, Xenon) and anti-apoptotic interventions (nuclear factor kappa B- and c-jun N-terminal kinase inhibition); in a later stage stimulation of neurotrophic properties in the neonatal brain (erythropoietin, growth factors) can be targeted to promote neuronal and oligodendrocyte regeneration. Combination of pharmacological means of treatment with moderate hypothermia, which is accepted now as a meaningful therapy, is probably the next step in clinical treatment to fight post-asphyxial brain damage. Further studies should be directed at a more rational use of therapies by determining the optimal time and dose to inhibit the different potentially destructive molecular pathways or to enhance endogenous repair while at the same time avoiding adverse effects of the drugs used.
Export Options
About this article
Cite this article as:
Fan Xiyong, Kavelaars Annemieke, J. Heijnen Cobi, Groenendaal Floris and van Bel Frank, Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic Brain Injury, Current Neuropharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157015910793358150
DOI https://dx.doi.org/10.2174/157015910793358150 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Emotion (Dys)regulation: An integration of Pharmacological, Neurobiological, and Psychological Frameworks
Emotion regulation is a critical aspect of mental well-being and interpersonal relationships. To fully understand and effectively address emotion regulation, an integrative approach that considers pharmacological, neurobiological, and psychological frameworks is essential. Pharmacological interventions, such as medications targeting neurotransmitter imbalances, can play a significant role in managing emotional dysregulation. Understanding ...read more
Enhancing Neuropharmacology with Home Cage Monitoring, Advanced Delivery and Stimulation Technologies, and Artificial Intelligence
Home cage monitoring (HCM) technologies have revolutionized neuropharmacological research by enabling continuous, non-invasive observation of rodents in their natural environments. Complementary advancements such as 24/7 continuous drug delivery systems (e.g., implantable pumps) and wireless neurostimulation methods—including optogenetics—offer precise methods for modulating neural activity and administering pharmacological agents without disrupting the ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interaction of Nerve Agent Antidotes with Cholinergic Systems
Current Medicinal Chemistry The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets Role of Protein Conformational Dynamics and DNA Integrity in Relevance to Neuronal Cell Death in Neurodegeneration
Current Alzheimer Research Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Monocyclic and Fused Azines and Azoles as Histamine H<sub>4</sub> Receptor Ligands
Current Medicinal Chemistry Molecular Function of Tocopherols in Age Related Diseases
Current Pharmaceutical Design Leukotrienes and Antileukotriene Therapy in Allergic Rhinitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Therapeutic Potential of Ultrasound Neuromodulation in Decreasing Neuropathic Pain: Clinical and Experimental Evidence
Current Neuropharmacology A Direct Correlation between Red Blood Cell Indices and Cognitive Impairment After Aneurysmal Subarachnoid Hemorrhage (aSAH)
Current Neurovascular Research Novel Coronavirus SARS-CoV-2 (COVID-19) and Pregnancy: A Hypothetical View
Endocrine, Metabolic & Immune Disorders - Drug Targets Kinins and Cardiovascular Diseases
Current Pharmaceutical Design The Vasoactive Role of Nitric Oxide: Physiological and Morphological Aspects
Current Pharmaceutical Biotechnology In Utero Exposure to Phthalates and Fetal Development
Current Medicinal Chemistry Some Important Dietary Polyphenolic Compounds: An Anti-inflammatory and Immunoregulatory Perspective
Mini-Reviews in Medicinal Chemistry Pharmacological Overview and Future Perspectives of Cholinergic Therapy in Alzheimers Disease
Current Drug Therapy Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine The Roles of MicroRNAs in Heart Diseases: A Novel Important Regulator
Current Medicinal Chemistry Charcot-Marie-Tooth Disease and Related Hereditary Neuropathies: From Gene Function to Associated Phenotypes
Current Molecular Medicine Heme Oxygenase Overexpression Attenuates Glucose-Mediated Oxidative Stress in Quiescent Cell Phase: Linking Heme to Hyperglycemia Complications
Current Neurovascular Research